^
Association details:
| Biomarker: | FGF amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | lucitanib (E 3810) (FGFR inhibitor, VEGFR inhibitor, Tyrosine kinase inhibitor, PDGFR α-β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
Excerpt:
...FGF aberrant, i.e. they suffered from a tumor harboring FGFR1 or FGF3/4/19 amplification...In assessable FGF-aberrant breast cancer patients, 50% (6 of 12) achieved RECIST partial response with a median PFS of 40.4 weeks for all treated patients.
DOI:
10.1093/annonc/mdu390
